AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Editas Medicine to Participate in Upcoming Investor Conferences.
ByAinvest
Wednesday, Aug 27, 2025 1:36 pm ET1min read
Editas Medicine, a gene editing company, announced management participation in three upcoming investor conferences in September. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Baird Global Healthcare Conference. The presentations will cover the company's pipeline of transformative in vivo medicines for serious diseases. The webcasts and presentations will be available on Editas Medicine's website.
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, has announced its management's participation in three upcoming investor conferences in September. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Baird Global Healthcare Conference. These conferences will provide investors with an opportunity to learn about the company's pipeline of transformative in vivo medicines for serious diseases.The Wells Fargo Healthcare Conference, scheduled for Wednesday, September 3 in Boston, will feature one-on-one meetings. The Cantor Global Healthcare Conference, taking place on Thursday, September 4 in New York, will feature a fireside chat with a webcast and one-on-one meetings. The Baird Global Healthcare Conference, on Tuesday, September 9 in New York, will include a presentation and one-on-one meetings. Webcasts of Editas Medicine’s presentations will be available on the company's website, with replays available for approximately 30 days following each event.
Editas Medicine is focused on translating the power of CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines. The company aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine holds exclusive licenses for Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.
Investors and financial professionals are encouraged to attend these events or access the webcasts for the latest information and updates on Editas Medicine's progress.
References:
[1] https://www.morningstar.com/news/globe-newswire/9518586/editas-medicine-to-participate-in-upcoming-investor-conferences
[2] https://www.globenewswire.com/news-release/2025/08/27/3140088/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet